Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Lymphoma, Non-Hodgkin

ClinicalTrials.gov lists 6,368 trials for Lymphoma, Non-Hodgkin or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 301.

MeSH D008228 Neoplasms Neoplasm C04 C15 C20 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 1,572 Phase 1/2 Phase 1/2 765 Phase 2 Phase 2 2,111 Phase 2/3 Phase 2/3 53 Phase 3 Phase 3 519 Phase 4 Phase 4 110 Not applicable Not applicable 539 Observational Observational 672 Phase 1 Phase 1 1,572 Phase 1/2 Phase 1/2 765 Phase 2 Phase 2 2,111 Phase 2/3 Phase 2/3 53 Phase 3 Phase 3 519 Phase 4 Phase 4 110 Not applicable Not applicable 539 Observational Observational 672

Trials per phase (log scale)

2 more sections with rows

2,284 of the 6,368 trials are tagged with Lymphoma, Non-Hodgkin itself; the rest are tagged with a narrower condition beneath it.

Get the Lymphoma, Non-Hodgkin report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Lymphoma, Non-Hodgkin trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 17 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 349

1990: 7 trials (Not applicable 1, Phase 2 5, Phase 1 1) 1991: 5 trials (Not applicable 1, Phase 2 3, Phase 1 1) 1992: 11 trials (Observational 2, Phase 3 1, Phase 2 6, Phase 1/2 1, Phase 1 1) 1993: 7 trials (Observational 1, Phase 3 2, Phase 2 4) 1994: 12 trials (Observational 1, Phase 3 5, Phase 2 4, Phase 1 2) 1995: 22 trials (Phase 4 2, Phase 3 5, Phase 2 10, Phase 1/2 1, Phase 1 4) 1996: 31 trials (Observational 4, Not applicable 2, Phase 3 2, Phase 2 15, Phase 1 8) 1997: 54 trials (Observational 5, Not applicable 3, Phase 3 10, Phase 2/3 1, Phase 2 18, Phase 1/2 4, Phase 1 13) 1998: 69 trials (Observational 2, Not applicable 2, Phase 4 1, Phase 3 9, Phase 2/3 1, Phase 2 36, Phase 1/2 4, Phase 1 14) 1999: 85 trials (Observational 3, Not applicable 4, Phase 3 13, Phase 2/3 1, Phase 2 28, Phase 1/2 7, Phase 1 29) 2000: 104 trials (Observational 6, Not applicable 7, Phase 4 1, Phase 3 15, Phase 2 50, Phase 1/2 8, Phase 1 17) 2001: 85 trials (Observational 4, Not applicable 9, Phase 4 1, Phase 3 13, Phase 2 34, Phase 1/2 5, Phase 1 19) 2002: 97 trials (Observational 5, Not applicable 7, Phase 4 2, Phase 3 8, Phase 2/3 1, Phase 2 45, Phase 1/2 11, Phase 1 18) 2003: 131 trials (Observational 4, Not applicable 10, Phase 4 3, Phase 3 23, Phase 2/3 1, Phase 2 56, Phase 1/2 17, Phase 1 17) 2004: 162 trials (Observational 10, Not applicable 12, Phase 4 3, Phase 3 16, Phase 2/3 1, Phase 2 74, Phase 1/2 14, Phase 1 32) 2005: 159 trials (Observational 11, Not applicable 10, Phase 4 2, Phase 3 14, Phase 2/3 1, Phase 2 80, Phase 1/2 16, Phase 1 25) 2006: 177 trials (Observational 10, Not applicable 5, Phase 4 6, Phase 3 16, Phase 2/3 1, Phase 2 82, Phase 1/2 21, Phase 1 36) 2007: 207 trials (Other 1, Observational 19, Not applicable 16, Phase 4 1, Phase 3 18, Phase 2/3 1, Phase 2 85, Phase 1/2 16, Phase 1 50) 2008: 183 trials (Observational 33, Not applicable 11, Phase 4 2, Phase 3 12, Phase 2/3 1, Phase 2 65, Phase 1/2 23, Phase 1 36) 2009: 173 trials (Other 1, Observational 18, Not applicable 9, Phase 4 5, Phase 3 10, Phase 2 73, Phase 1/2 15, Phase 1 42) 2010: 191 trials (Observational 20, Not applicable 14, Phase 4 6, Phase 3 16, Phase 2/3 3, Phase 2 69, Phase 1/2 28, Phase 1 35) 2011: 189 trials (Observational 19, Not applicable 6, Phase 4 6, Phase 3 19, Phase 2 73, Phase 1/2 18, Phase 1 48) 2012: 179 trials (Observational 19, Not applicable 16, Phase 4 6, Phase 3 20, Phase 2 58, Phase 1/2 20, Phase 1 40) 2013: 179 trials (Observational 16, Not applicable 9, Phase 4 2, Phase 3 24, Phase 2/3 2, Phase 2 49, Phase 1/2 18, Phase 1 59) 2014: 172 trials (Observational 12, Not applicable 14, Phase 4 5, Phase 3 16, Phase 2 41, Phase 1/2 36, Phase 1 48) 2015: 207 trials (Observational 20, Not applicable 16, Phase 4 2, Phase 3 22, Phase 2/3 1, Phase 2 69, Phase 1/2 32, Phase 1 45) 2016: 264 trials (Observational 29, Not applicable 16, Phase 4 9, Phase 3 14, Phase 2/3 6, Phase 2 79, Phase 1/2 44, Phase 1 67) 2017: 285 trials (Observational 31, Not applicable 29, Phase 4 4, Phase 3 25, Phase 2/3 4, Phase 2 76, Phase 1/2 43, Phase 1 73) 2018: 248 trials (Observational 22, Not applicable 15, Phase 4 2, Phase 3 12, Phase 2 82, Phase 1/2 33, Phase 1 82) 2019: 288 trials (Observational 28, Not applicable 22, Phase 4 10, Phase 3 15, Phase 2/3 2, Phase 2 78, Phase 1/2 32, Phase 1 101) 2020: 301 trials (Observational 43, Not applicable 17, Phase 4 1, Phase 3 12, Phase 2/3 3, Phase 2 93, Phase 1/2 39, Phase 1 93) 2021: 333 trials (Observational 37, Not applicable 35, Phase 4 7, Phase 3 25, Phase 2/3 2, Phase 2 93, Phase 1/2 44, Phase 1 90) 2022: 328 trials (Observational 36, Not applicable 45, Phase 4 4, Phase 3 23, Phase 2/3 2, Phase 2 78, Phase 1/2 48, Phase 1 92) 2023: 336 trials (Observational 56, Not applicable 45, Phase 4 5, Phase 3 16, Phase 2/3 1, Phase 2 76, Phase 1/2 49, Phase 1 88) 2024: 349 trials (Observational 49, Not applicable 49, Phase 4 2, Phase 3 18, Phase 2/3 6, Phase 2 113, Phase 1/2 34, Phase 1 78) 2025: 342 trials (Observational 52, Not applicable 39, Phase 4 8, Phase 3 19, Phase 2/3 5, Phase 2 105, Phase 1/2 39, Phase 1 75)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 302
2025 342
2024 349
2023 336
2022 328
2021 333
2020 301
2019 288
2018 248
2017 285

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 350 trials starting in 2026 and about 350 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 887 trials still running at the 2026-10-09 snapshot; registered median of 41 months across 3,668 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Lymphoma, Non-Hodgkin trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 1,572
Phase 1/2 765
Phase 2 2,111
Phase 2/3 53
Phase 3 519
Phase 4 110
Not applicable 539
Observational 672
Expanded access 26
Unknown 1

How many Lymphoma, Non-Hodgkin trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 264
Recruiting 909
Enrolling by invitation 29
Active, not recruiting 467
Available 9

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Lymphoma, Non-Hodgkin trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 301
Hoffmann-La Roche 76
Novartis Pharmaceuticals 64
Celgene 56
Pfizer 44

Which drugs are being tested for Lymphoma, Non-Hodgkin? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
RITUXIMAB 909
Cytoxan 736
Prednisone 312
Melphalan 134

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 354
Vincristina 347
Doxorubicine 323
Etoposid 279
X: Lenalidomide 218

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Lymphoma, Non-Hodgkin trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Febrile neutropenia 3,370 401
Pneumonia 2,611 375
Neutrophil count decreased 2,091 151
Pyrexia 1,740 295
Sepsis 1,476 370

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Lymphoma, Non-Hodgkin? (747)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma. Blood 2025 Yes
Trends in physical functioning in acute lymphoblastic leukemia and non-Hodgkin lymphoma survivors across three decades. Journal of cancer survivorship : research and practice 2025 Yes
A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma. Clinical pharmacology and therapeutics 2025 Yes
ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma. Molecular therapy : the journal of the American Society of Gene Therapy 2025 Yes
A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study. British journal of haematology 2025 Yes

Showing 5 of 747 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (6)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Non-Hodgkin lymphoma Annual incidence 1-5 / 10 000 Europe Not stated Exact
Non-Hodgkin lymphoma Point prevalence 1-5 / 10 000 Europe Not stated Exact
Non-Hodgkin lymphoma Point prevalence 1-5 / 10 000 Europe Not stated Unspecified
Non-Hodgkin lymphoma Point prevalence 1-5 / 10 000 Europe Not stated Exact
Non-Hodgkin lymphoma Annual incidence 1-5 / 10 000 Europe Not stated Unspecified

Showing 5 of 6 prevalence observations.

Start your 14-day trial Email me all 6 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Non-Hodgkin lymphoma 547 Exact Orphadata Science knowledge files, Product 1
Non-Hodgkin lymphoma 547 Exact Orphanet Rare Disease Ontology (ORDO)

Sub-conditions in MeSH (5)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages